Britain and America have concluded a significant trade agreement that will keep zero duties on British pharmaceutical exports entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial products will remain at zero for a period of 36 months.
This deal comes after recent warnings to hike import taxes on patented pharmaceutical products, with potential rates discussed up to one hundred percent.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and brings long-overdue equity to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Impact
Medicines represent one of the the United Kingdom's most significant goods shipped to the US, which is easily the primary destination for large UK drugmakers.
Statistics indicate that in the one-year period prior to September, the UK sold medicines worth billions to the US. This value represented nearly one-fifth of total UK exports in that span.
"This agreement protects jobs, boosts capital expenditure and sets the stage for the UK to become a global hub for biotech and pharma," a minister commented.
Specific UK Commitments
The agreement includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it considers new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to raise total NHS spending on treatments from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Last year, repayments topped 20%.
Industry Background
The pact comes amid a protracted row between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that US patients were paying significantly more for the identical medicines than people in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been pledged toward projects in the United States.
The Science Minister stated that the NHS must invest a greater share on treatments, noting that its budget allocation on drugs had declined as a share of its total funding over the past decade.
